Chairman, Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center New York, New York, United States
Comprehensive genomic profiling (CGP) using a matched tumor-normal approach can help improve somatic detection rate and streamline interpretation.
MSK-IMPACT® powered with SOPHiA DDM™ is a CGP solution that leverages matched tumor-normal sequencing to filter germline variants and may also identify clonal hematopoietic variants, revealing mutations of true somatic origin. The end-to-end application combines the clinical expertise of Memorial Sloan Kettering Cancer Center (MSK) with the robust analytics of SOPHiA DDM™.
Join us and experts from MSK to: • Discover the clinical utility of MSK-IMPACT® at MSK. • Explore the decentralized workflow, robust technology, and analytical performance of MSK-IMPACT® powered with SOPHiA DDM™.
